clinical trial · NCT04027647
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore·phase2·active not recruiting·n = 118
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IVRecurrent NSCLCEGFR Positive Non-Small Cell Lung CancerDacomitinib
brief summary
This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.
started
Sep 11, 2019
primary completion
Mar 31, 2026
completion
Mar 31, 2026
last updated
Jun 12, 2025
official title
A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol